Literature DB >> 11971129

Cognitive outcomes and predictive factors in epilepsy.

Kimford J Meador1.   

Abstract

Although most patients with epilepsy have normal cognitive abilities, they are at increased risk for cognitive deficits. Multiple factors contribute to this risk including antiepileptic drugs (AEDs), which not only reduce neuronal irritability but may also impair neuronal excitability. The major cognitive effects of AEDs are impaired attention, vigilance, and psychomotor speed, but secondary effects on other cognitive functions can be seen. The adverse cognitive effects of AEDs are offset in part by reduced seizures. In general, the cognitive effects of AEDs are less than the sum total of other factors, but because AEDs are the major therapeutic modality for epilepsy, they are of special concern. AED-induced cognitive side effects are increased with rapid initiation, higher dosages, and polytherapy. Differential cognitive effects can be seen (e.g., worse performance on phenobarbital), but the magnitude of cognitive effects is relatively modest effects for most AEDs. However, even this modest effect can be clinically significant and impact the patient's quality of life. In addition, some patient groups may be at particular risk (e.g., elderly, children, fetus). The ultimate therapeutic goal is to control seizures with no or minimal side effects. The cognitive profile of an AED is but one factor in the selection of therapeutic options. Ongoing seizures can be detrimental to both cognition and quality of life. Patients who are refractory or intolerant to AED therapy should be referred for video EEG monitoring to confirm the seizure diagnosis and determine if the patient is a candidate for epilepsy surgery.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11971129     DOI: 10.1212/wnl.58.8_suppl_5.s21

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  51 in total

Review 1.  Early epilepsy surgery.

Authors:  Samuel Wiebe
Journal:  Curr Neurol Neurosci Rep       Date:  2004-07       Impact factor: 5.081

2.  The Art of Managing Conversions between Antiepileptic Drugs: Maximizing Patient Tolerability and Quality of Life.

Authors:  Erik K St Louis
Journal:  Pharmaceuticals (Basel)       Date:  2010-09-01

3.  Multi-domain neurocognitive classification of primary brain tumor patients prior to radiotherapy on a prospective clinical trial.

Authors:  Roshan Karunamuni; Kathryn R Tringale; Jeffrey Burkeen; Michelle D Tibbs; Minh-Phuong Huynh-Le; Naeim Bahrami; Deborah Marshall; Tyler M Seibert; Carrie R McDonald; Jona A Hattangadi-Gluth
Journal:  J Neurooncol       Date:  2019-11-23       Impact factor: 4.130

Review 4.  Functional neuroimaging in the preoperative evaluation of children with drug-resistant epilepsy.

Authors:  Sandeep Sood; Harry T Chugani
Journal:  Childs Nerv Syst       Date:  2006-06-24       Impact factor: 1.475

5.  Resistance Exercise Reduces Seizure Occurrence, Attenuates Memory Deficits and Restores BDNF Signaling in Rats with Chronic Epilepsy.

Authors:  Alexandre Aparecido de Almeida; Sérgio Gomes da Silva; Glauber Menezes Lopim; Diego Vannucci Campos; Jansen Fernandes; Francisco Romero Cabral; Ricardo Mario Arida
Journal:  Neurochem Res       Date:  2017-01-11       Impact factor: 3.996

Review 6.  Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities.

Authors:  Martin Klein
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

7.  Cognitive effects of antiepileptic drugs.

Authors:  Sung-Pa Park; Soon-Hak Kwon
Journal:  J Clin Neurol       Date:  2008-09-30       Impact factor: 3.077

8.  Satisfaction with life domains in people with epilepsy.

Authors:  Rosemarie Kobau; Cecily Luncheon; Matthew M Zack; Ross Shegog; Patricia H Price
Journal:  Epilepsy Behav       Date:  2012-11-13       Impact factor: 2.937

9.  Minimizing AED adverse effects: improving quality of life in the interictal state in epilepsy care.

Authors:  Erik K St Louis; Erik K Louis
Journal:  Curr Neuropharmacol       Date:  2009-06       Impact factor: 7.363

10.  Truly "rational" polytherapy: maximizing efficacy and minimizing drug interactions, drug load, and adverse effects.

Authors:  Erik K St Louis
Journal:  Curr Neuropharmacol       Date:  2009-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.